Inovio's dMAb(TM) PD-1 Checkpoint Inhibitors Demonstrate Highe...
PLYMOUTH MEETING, Pennsylvania, Jan. 15, 2019 /PRNewswire-AsiaNet/ -- -- PD-1 DNA-encoded monoclonal antibodies (dMAbs) highlighted in a paper published in cancer journal OncotargetInovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the successful development of optimized DNA-encoded monoclonal antibodies...
Read more https://view-release/?pr-id=77071